MedinCell

Executive Summary

MedinCell is a French biotechnology company pioneering long-acting injectable (LAI) therapies through its proprietary BEPO® technology. The platform enables sustained drug release over weeks to months, improving patient adherence and treatment outcomes. MedinCell's lead candidate, mdc-TJK (Methylphenidate LAI for schizophrenia), is in Phase 3 development with a potential NDA submission in 2026. Other programs include pain management and infectious diseases. With a robust technology platform and strategic partnerships (e.g., Teva), MedinCell is positioned to address significant unmet needs in chronic disease management. The company's private status and focus on scalable manufacturing provide a strong operational base for future growth.

Upcoming Catalysts (preview)

• Q4 2026FDA NDA submission for mdc-TJK (schizophrenia)60% success
• H1 2027Phase 3 data readout for mdc-CWM (chronic pain)50% success
• Q2 2026New partnership or licensing deal for BEPO platform70% success